EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Gastroparesis induced by glucagon-like peptide-1 receptor agonists: A systematic review of clinical features, diagnosis, management, and outcomes

Tope Olubodun iD, Morenike Adedoyin Osundina, David Olubukunmi Soyoye, Natalia Maria Bim de Oliveira, Ayodeji Bamidele Olubodun, Oluwatoyin Olanrewaju Ogundele

PLOS One · 2026

DOI: 10.1371/journal.pone.0354497 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift PLOS One, 2026. Verfasst von Tope Olubodun und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Community Medicine and Primary Care, Federal Medical Center Abeokuta, Abeokuta, Ogun State, Nigeria. Hauptthemen laut MEDLINE: Gastroparesis, Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Hypoglycemic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used for the treatment of type 2 diabetes mellitus and obesity. Although gastrointestinal adverse effects are common, gastroparesis is an under-recognised but clinically important complication. This systematic review summarises published evidence on the presentation, diagnosis, management, and outcomes of gastroparesis associated with GLP-1RA therapy in real-world clinical practice.

Methods

A systematic review was conducted in accordance with PRISMA 2020 guidelines. PubMed, Embase, Scopus, and Web of Science were searched from inception to October 2025 for reports of symptomatic gastroparesis associated with GLP-1RA use. Eligible studies included case reports, case series, observational studies, and clinical trials involving adults treated with GLP-1RAs for diabetes or weight loss. Data extraction focused on patient characteristics, GLP-1RA exposure, clinical presentation, diagnostic findings, management strategies, and outcomes. Methodological quality was assessed using the Joanna Briggs Institute checklist for case reports.

Results

Twelve case reports describing 13 patients met inclusion criteria. Most patients were female and had type 2 diabetes mellitus, though cases also occurred in non-diabetic individuals. Semaglutide was the most frequently implicated agent, followed by liraglutide, dulaglutide, and exenatide. Symptom onset ranged from hours to several months after treatment initiation, commonly following dose escalation or inappropriate re-initiation. Presentations varied from acute to chronic. Reported symptoms included nausea, vomiting, abdominal pain, bloating, early satiety, and oral intolerance. Diagnostic evaluation often demonstrated gastric distension or retained gastric contents on imaging or endoscopy in the absence of mechanical obstruction. Gastric emptying scintigraphy confirms delayed emptying in selected cases. Management primarily involved supportive and symptomatic care. Discontinuation of the offending GLP-1RA led to symptom resolution in all reported patients.

Conclusion

GLP-1 receptor agonists may induce or worsen gastroparesis in both diabetic and non-diabetic patients, particularly following rapid dose escalation or inappropriate dosing. Awareness of this association is essential for timely diagnosis and management. Withdrawal of the causative agent is central to treatment and is associated with favourable outcomes and reversibility of gastric dysfunction. Careful patient selection, gradual dose titration, and monitoring for persistent gastrointestinal symptoms are recommended to optimise the safe use of GLP-1RAs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GastroparesisGlucagon-Like Peptide-1 Receptor AgonistsDiabetes Mellitus, Type 2Hypoglycemic AgentsHumansSemaglutideExenatideFemaleLiraglutideGlucagon-Like PeptidesRecombinant Fusion ProteinsMaleGlucagon-Like Peptide-1 ReceptorTreatment OutcomeImmunoglobulin Fc Fragments

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsSemaglutideExenatideHypoglycemic AgentsLiraglutideGlucagon-Like PeptidesdulaglutideRecombinant Fusion ProteinsGlucagon-Like Peptide-1 ReceptorImmunoglobulin Fc Fragments

Autor:innen und Institutionen

  • Department of Community Medicine and Primary Care, Federal Medical Center Abeokuta, Abeokuta, Ogun State, Nigeria.
  • Department of Medicine, University of Ibadan, Ibadan, Oyo State, Nigeria.
  • Department of Medicine, Obafemi Awolowo University, Ile-Ife, Osun State, Nigeria.
  • Ferring Pharmaceuticals, São Paulo, São Paulo, Brazil.
  • Accident and Emergency Department, Olabisi Onabanjo University Teaching Hospital, Sagamu, Ogun State, Nigeria.
  • Nats'oojeh Hospital and Health Centre, Fort St James, British Columbia, Canada.

ORCID-Profile: Tope Olubodun

Zitieren

APA

Olubodun, T., Osundina, M. A., Soyoye, D. O., de Oliveira, N. M. B., Olubodun, A. B., & Ogundele, O. O. (2026). Gastroparesis induced by glucagon-like peptide-1 receptor agonists: A systematic review of clinical features, diagnosis, management, and outcomes. PLOS One. https://doi.org/10.1371/journal.pone.0354497

Vancouver

Olubodun T, Osundina MA, Soyoye DO, de Oliveira NMB, Olubodun AB, Ogundele OO. Gastroparesis induced by glucagon-like peptide-1 receptor agonists: A systematic review of clinical features, diagnosis, management, and outcomes. PLOS One. 2026. doi:10.1371/journal.pone.0354497

BibTeX
@article{Olubodun2026,
  author = {Olubodun, Tope and Osundina, Morenike Adedoyin and Soyoye, David Olubukunmi and de Oliveira, Natalia Maria Bim and Olubodun, Ayodeji Bamidele and Ogundele, Oluwatoyin Olanrewaju},
  title = {Gastroparesis induced by glucagon-like peptide-1 receptor agonists: A systematic review of clinical features, diagnosis, management, and outcomes},
  journal = {PLOS One},
  year = {2026},
  doi = {10.1371/journal.pone.0354497}
}
Kostenlos starten →